Amniotics Dirección

Dirección controles de criterios 1/4

El CEO de Amniotics' es Marcus Larsson, nombrado en Aug 2022, tiene una permanencia de 1.67 años. posee directamente un 0.51% de las acciones de la empresa, con un valor de SEK54.45K. La antigüedad media del equipo directivo y de la junta directiva es de 1.7 años y 3.3 años, respectivamente.

Información clave

Marcus Larsson

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.8yrs
Participación del CEO	0.5%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Marcus Larsson (50 yo)

1.8yrs

Permanencia

Mr. Marcus Larsson, Ph D., has been a Director of Amniotics AB (publ) since 2015 and serves as its Chief Executive Officer from August 2022. He is also Chairman of the Board of Camurus Lipid Research Found...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Marcus Larsson	Founding Member	1.8yrs	sin datos	0.51% SEK 54.4k
Gerton Jonsson	Chief Financial Officer	less than a year	sin datos	sin datos
Jan Talts	Chief Operating Officer	7.3yrs	sin datos	0.0027% SEK 284.6
Sidonie Karlsson	Head of Manufacturing	no data	sin datos	sin datos

1.8yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AMNI no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Marcus Larsson	Founding Member	9.3yrs	sin datos	0.51% SEK 54.4k
Peter Jensen	Independent Chairman of the Board	3.3yrs	sin datos	sin datos
Ingrid Heiman	Independent Director	3.3yrs	sin datos	0.000070% SEK 7.5
Fredrik Tiberg	Independent Director	3.3yrs	sin datos	0.030% SEK 3.2k
Christopher Bravery	Independent Director	3.3yrs	sin datos	sin datos

3.3yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de AMNI se considera experimentada (3.3 años de antigüedad promedio).

Amniotics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Amniotics AB (publ), Annual General Meeting, May 22, 2024

Founding Member exercised options to buy kr949k worth of stock.

Amniotics AB (publ), Annual General Meeting, May 22, 2023

High number of new and inexperienced directors

Amniotics AB (Publ) Announces Executive Changes

High number of new and inexperienced directors

Recent updates

Magle Chemoswed Holding AB (publ) (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (publ) (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.

Amniotics AB (publ) to Report First Half, 2024 Results on Aug 20, 2024

Amniotics AB (publ), Annual General Meeting, May 22, 2024

No longer forecast to breakeven

New minor risk - Profitability

Amniotics AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Amniotics AB (publ) Receives Positive Opinion on Orphan Designation for PulmoStem from the European Medicines Agency for the Treatment of Primary Graft Dysfunction Following Lung Transplantation

Amniotics AB (publ) has completed a Composite Units Offering.

Amniotics AB (publ) has completed a Composite Units Offering.

Amniotics AB (publ) Receives Final Clinical Study Report for the Phase Ib Clinical Trial

New major risk - Financial position

New minor risk - Financial position

Founding Member exercised options to buy kr949k worth of stock.

Amniotics AB (publ) Receives Positive Topline Results from Clinical Phase Ib Study with PulmoStem

Amniotics AB (publ), Annual General Meeting, May 22, 2023

Forecast to breakeven in 2024

Amniotics AB (publ) Completes Phase Ib Study of PulmoStem

High number of new and inexperienced directors

Amniotics AB (publ) Invites by European Innovation Council to Finalise Grant Agreement with the as Part of Consortium Set to Receive Grant of EUR 3.8 Million from the EIC Pathfinder Programme

Amniotics AB (publ) Announces First Patient Dosed in Phase Ib Study with PulmoStem to Treat Severe Viral Lung Disease

Amniotics Phase Ib Study of Pulmostem™ to Include Broader Patient Population

Amniotics AB (Publ) Announces Executive Changes

High number of new and inexperienced directors

Amniotics AB (publ) Phase I/II Study of PulmoStem™ in Hospitalized COVID-19 Patients Ready to Start

Amniotics AB (Publ) Announces the Resignation of Anders Månsson from the Board

Amniotics Receives Approval for Phase I/II Study of Pulmostem in Hospitalized Covid-19 Patients

Amniotics Secures Funding of SEK 4.8 Million from Vinnova to Develop Stem Cell Therapies

Amniotics submits CTA for Phase I/II trial in COVID-19 patients with PulmoStemTM

Amniotics Joins Vinnova Funded ’CAMP’ ’ to Improve Outcome of Lung Transplantations with Pulmostem™

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad